Guest guest Posted September 4, 2004 Report Share Posted September 4, 2004 In a message dated 9/4/04 1:45:22 PM Eastern Daylight Time, jsr1936@... writes: > An FDA ruling has forbidden Lane Labs to make and distribute MGN-3. > > > Oh no! Quote Link to comment Share on other sites More sharing options...
Guest guest Posted September 4, 2004 Report Share Posted September 4, 2004 On what basis? Any further info. would be appreciated. Bob Beiswenger Huntingdon Valley, Pa. MGN-3 banned! > > An FDA ruling has forbidden Lane Labs to make and distribute MGN-3. > > > > > Quote Link to comment Share on other sites More sharing options...
Guest guest Posted September 4, 2004 Report Share Posted September 4, 2004 From: szukidavis@... > > > An FDA ruling has forbidden Lane Labs to make and distribute MGN-3. > > > > Hi, Lane Labs now recommends a patented mushroom exract - AHCC. Notice how everything is money rlated. Patented means only Lane Labs can sell it. I recommend non patented (hence cheaper and generic) mushroom extract BETA GLUCAN. PSP and PSK are both types of BETA 1-3 d GLUCAN. 1: Altern Med Rev. 2000 Feb;5(1):4-27. Click here to read The use of mushroom glucans and proteoglycans in cancer treatment. Kidd PM. Immunoceuticals can be considered as substances having immunotherapeutic efficacy when taken orally. More than 50 mushroom species have yielded potential immunoceuticals that exhibit anticancer activity in vitro or in animal models and of these, six have been investigated in human cancers. All are non-toxic and very well tolerated. Lentinan and schizophyllan have little oral activity. Active Hexose Correlated Compound (AHCC) is poorly defined but has shown early clinical promise. Two proteoglycans from Coriolus versicolor - PSK (Polysaccharide-K) and PSP (Polysaccharide-Peptide - have demonstrated the most promise. In Japanese trials since 1970, PSK significantly extended survival at five years or beyond in cancers of the stomach, colon- rectum, esophagus, nasopharynx, and lung (non-small cell types), and in a HLA B40-positive breast cancer subset. PSP was subjected to Phase II and Phase III trials in China. In double-blind trials, PSP significantly extended five-year survival in esophageal cancer. PSP significantly improved quality of life, provided substantial pain relief, and enhanced immune status in 70-97 percent of patients with cancers of the stomach, esophagus, lung, ovary, and cervix. PSK and PSP boosted immune cell production, ameliorated chemotherapy symptoms, and enhanced tumor infiltration by dendritic and cytotoxic T-cells. Their extremely high tolerability, proven benefits to survival and quality of life, and compatibility with chemotherapy and radiation therapy makes them well suited for cancer management regimens. PMID: 10696116 [PubMed - indexed for MEDLINE] Quote Link to comment Share on other sites More sharing options...
Guest guest Posted September 5, 2004 Report Share Posted September 5, 2004 See article dated 13 July 2004 and titled " U.S. District Judge Issues Permanent Injunction Against Lane Labs-USA, Inc. and Orders Firm to Refund Money to Purchasers of Illegally Marketed Unapproved Drugs " at http://www.fda.gov/bbs/topics/news/2004/NEW01086.html > On what basis? Any further info. would be appreciated. > > Bob Beiswenger > Huntingdon Valley, Pa. Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.